Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Streamlining Documentation for Paul-Ehrlich-Institut (PEI) Submissions for Gene Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Streamlining Documentation for Paul-Ehrlich-Institut (PEI) Submissions for Gene Therapies

Streamlining Viral Vector Documentation for Paul-Ehrlich-Institut (PEI) Submissions

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence Accelerating Next-Generation Therapies.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Executive Summary

For viral vector programs targeting European clinical trials, the Paul-Ehrlich-Institut (PEI) requires a highly detailed Chemistry, Manufacturing, and Controls (CMC) data package. Successful Investigational Medicinal Product Dossier (IMPD) submissions depend on a documentation strategy established long before GxP manufacturing begins. This involves meticulous characterization of plasmids, rigorous qualification of analytical methods, and a transparent technology transfer process that generates a coherent narrative for regulators. Franklin Biolabs provides the CMC framework and GxP-compliant documentation support to prepare viral vector programs for PEI review, helping sponsors navigate the path from process development to clinical readiness within an 18-24 month timeline.

Technical FAQ

    What is the primary focus of the PEI for AAV or Lentivirus vector submissions?

    The PEI places significant emphasis on product characterization, particularly concerning vector purity (e.g., empty vs. full capsids), identity, and the validation status of potency assays. They require a clear line of sight from the starting materials, like the plasmid DNA, through the entire manufacturing process to the final drug product.

    How early should a documentation strategy for an IMPD be established?

    Documentation for an IMPD should begin during late-stage process development. Key process parameters, analytical methods, and raw material specifications defined at this stage form the basis of the CMC section (Module 3) of the dossier.

    What are common documentation gaps that delay PEI submissions?

    Common gaps include incomplete plasmid lineage and characterization data, insufficiently qualified analytical methods for product-related impurities, and poorly documented process changes during scale-up. A lack of robust comparability data can also trigger significant regulatory questions.

Aligning CMC Documentation with PEI Expectations

The PEI’s regulatory stance prioritizes a deep understanding of the manufacturing process and its relationship to the final vector’s quality attributes. Successful submissions are built from a deliberately constructed data package that demonstrates consistent process control and product understanding, creating a coherent narrative for regulators. This aligns with the principles of responsible therapeutic development, where a well-documented safety and quality profile is a prerequisite for any novel AAV or lentiviral vector program (PMID: 40643951).

Our approach focuses on building the IMPD narrative from the ground up.

  • Plasmid DNA Control: We establish full traceability and characterization of all starting plasmids, a frequent point of scrutiny for German regulators.

  • Process Parameter Definition: We assist in defining and justifying process parameters during development, ensuring they are well-documented ahead of GxP manufacturing.

  • Analytical Method Qualification: All assays for release and characterization are qualified in a phase-appropriate manner, generating the robust data required by the PEI.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

The Role of Tech Transfer in Regulatory Readiness

A structured technology transfer from a process development lab to a GxP manufacturing suite is a key data-generating event for a regulatory submission. The transfer protocol itself, along with the engineering and validation run reports, provides objective evidence of process reproducibility and scalability.

The data generated during this process becomes a component of the regulatory file. By managing this transition within our >100,000 sq ft facility, we ensure data integrity is maintained and that the information captured is directly suitable for regulatory review. This methodical approach supports a seamless tech transfer accelerating GMP readiness.

Core Documentation Components for Viral Vector IMPDs

Preparing Module 3 of an IMPD for the PEI requires specific attention to the unique aspects of viral vectors. We provide support in structuring and authoring the specific sections that regulators will evaluate.

Section (S) Focus Area Franklin Biolabs Contribution
S.2.1 Manufacturer(s) GxP-compliant facility information and quality systems overview.
S.2.2 Description of Manufacturing Process Detailed process flow diagrams and narrative descriptions.
S.2.3 Control of Materials Specifications for plasmids, cell banks, and raw materials.
S.3.2 Impurities Data packages on process- and product-related impurities.
S.4.1 Specifications Justification for drug substance release specifications.
S.4.2 Analytical Procedures Detailed descriptions of analytical methods used for release testing.

This structured approach has been a component of the strategy that supported a 100% successful IND rate for programs since 2019, with the Franklin Biolabs brand itself launching in 2024 to carry this expertise forward.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Technical Visualization: PEI Submission Documentation Pathway

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities